Plozasiran (REDEMPLO), an RNA interference therapy for familial chylomicronemia syndrome, has reached early commercial traction with approximately 180 patients treated and 83% median triglyceride reduction sustained over two years. This represents a distinct mechanistic approach to severe hypertriglyceridemia — addressing hepatic APOC3 production directly — with clinical efficacy and safety data that support its positioning as an alternative to competing inhibitors.
Key Points
- 180 patients treated; 30 new prescriptions weekly demonstrate uptake velocity
- 83% median triglyceride reduction maintained over two years, no acute pancreatitis
- RNA interference mechanism targets APOC3 production, differentiates from oral competitors
Longevity Analysis
Severe hypertriglyceridemia accelerates atherosclerosis and impairs multiple metabolic functions. Plozasiran's sustained triglyceride reduction addresses a root driver of cardiovascular risk in a genetically defined population where standard therapies fail. The two-year safety profile and mechanism of action — silencing APOC3 at the RNA level — suggest durability advantages over competing inhibitors. For practitioners managing familial chylomicronemia or treatment-resistant hypertriglyceridemia, this therapy expands the intervention toolkit when dietary modification and conventional agents prove insufficient, with particular relevance for reducing systemic inflammation and supporting healthy lipid metabolism in high-risk cohorts.
Original published by LT Wire.